CA2258882A1 - Compositions and methods for altering the biodistribution of biological agents - Google Patents

Compositions and methods for altering the biodistribution of biological agents

Info

Publication number
CA2258882A1
CA2258882A1 CA002258882A CA2258882A CA2258882A1 CA 2258882 A1 CA2258882 A1 CA 2258882A1 CA 002258882 A CA002258882 A CA 002258882A CA 2258882 A CA2258882 A CA 2258882A CA 2258882 A1 CA2258882 A1 CA 2258882A1
Authority
CA
Canada
Prior art keywords
biodistribution
methods
altering
compositions
biological agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002258882A
Other languages
French (fr)
Other versions
CA2258882C (en
Inventor
Thomas R. Porter
Patrick L. Iversen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska
Original Assignee
Thomas R. Porter
Patrick L. Iversen
Board Of Regents Of The University Of Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas R. Porter, Patrick L. Iversen, Board Of Regents Of The University Of Nebraska filed Critical Thomas R. Porter
Publication of CA2258882A1 publication Critical patent/CA2258882A1/en
Application granted granted Critical
Publication of CA2258882C publication Critical patent/CA2258882C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several therapeutic agents and can achieve site specific delivery of a therapeutic or diagnostic substance. This can allow for lower doses and for improved efficacy with drugs which traditionally reach targeted sites and can result in improved utility for agents such as oligonucleotides and polynucleotides which are plagued with problems with biodistribution.
CA002258882A 1996-06-28 1997-06-20 Compositions and methods for altering the biodistribution of biological agents Expired - Lifetime CA2258882C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/670,999 US5849727A (en) 1996-06-28 1996-06-28 Compositions and methods for altering the biodistribution of biological agents
US08/670,999 1996-06-28
PCT/US1997/010766 WO1998000172A2 (en) 1996-06-28 1997-06-20 Compositions and methods for altering the biodistribution of biological agents

Publications (2)

Publication Number Publication Date
CA2258882A1 true CA2258882A1 (en) 1998-01-08
CA2258882C CA2258882C (en) 2009-03-17

Family

ID=24692746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002258882A Expired - Lifetime CA2258882C (en) 1996-06-28 1997-06-20 Compositions and methods for altering the biodistribution of biological agents

Country Status (7)

Country Link
US (5) US5849727A (en)
EP (1) EP0938341B1 (en)
JP (2) JP4201348B2 (en)
AT (1) ATE260677T1 (en)
CA (1) CA2258882C (en)
DE (1) DE69727958T2 (en)
WO (1) WO1998000172A2 (en)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6176842B1 (en) * 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5648098A (en) * 1995-10-17 1997-07-15 The Board Of Regents Of The University Of Nebraska Thrombolytic agents and methods of treatment for thrombosis
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
JP2001507207A (en) 1996-05-01 2001-06-05 イマアーレクス・フアーマシユーチカル・コーポレーシヨン Methods for delivering compounds to cells
US5849727A (en) * 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
WO1998018495A2 (en) * 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US6331289B1 (en) * 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
BR9712683A (en) 1996-10-28 1999-10-19 Nyomed Imaging A S Diagnostic and / or therapeutically active targetable agent, combined formulation, process for preparing and using it, combined formulation, and processes for generating enhanced images of a human or non-human animal body and for in vitro targeting investigation by an agent.
IL129445A0 (en) * 1996-10-28 2000-02-29 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
ES2264159T3 (en) * 1996-10-28 2006-12-16 Amersham Health As IMPROVEMENTS IN / OR RELATED TO DIAGNOSTIC / THERAPEUTIC AGENTS.
US20070036722A1 (en) * 1996-10-28 2007-02-15 Pal Rongved Separation processes
WO1998018498A2 (en) * 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
US6676626B1 (en) 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US20030078227A1 (en) * 1998-07-02 2003-04-24 Greenleaf James F. Site-directed transfection with ultrasound and cavitation nuclei
WO2000002588A1 (en) * 1998-07-13 2000-01-20 The Board Of Regents Of The University Of Nebraska Targeted site specific drug delivery compositions and method of use
KR100649035B1 (en) * 1998-07-13 2006-11-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 네브라스카 Targeted site specific drug delivery compositions and method of use
US6309355B1 (en) * 1998-12-22 2001-10-30 The Regents Of The University Of Michigan Method and assembly for performing ultrasound surgery using cavitation
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6822086B1 (en) 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
DE60143085D1 (en) * 2000-05-17 2010-10-28 Univ Nebraska MORPHOLINO ANTISENSE OLIGOMERS AS ENZYMINHIBITORS FOR IMPROVING THE PHARMACOKINETICS OF AN ACTIVE SUBSTANCE
JP2002145784A (en) * 2000-11-10 2002-05-22 Ryuichi Morishita Biologically active medicament-introducing composition and method for using the same
DE10119522A1 (en) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Preparation and application of a suspension composition with an ultrasound contrast medium
EP1420643B1 (en) * 2001-07-10 2008-04-23 Sonogene, LLC Enhancement of transfection of dna into the liver
CA2464464A1 (en) * 2001-10-22 2003-05-01 Nucleonics Inc. Transfection kinetics and structural promoters
US7897382B2 (en) * 2001-10-22 2011-03-01 Alnylam Pharmaceuticals, Inc. Transfection kinetics and structural promoters
DE60209799T2 (en) 2001-12-03 2007-01-25 Ekos Corp., Bothell CATHETER WITH SEVERAL ULTRASOUND EMITTING PARTS
EP1488813A4 (en) * 2002-03-22 2005-04-06 Anges Mg Inc Compositions for delivering biologically active drug and method of using the same
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
US20030207907A1 (en) * 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
US7754238B2 (en) * 2002-05-03 2010-07-13 Avi Biopharma, Inc. Delivery of microparticle-conjugated drugs for inhibition of stenosis
EP1549352A4 (en) * 2002-05-06 2005-07-27 Nucleonics Inc Methods for delivery of nucleic acids
EP1540004A4 (en) * 2002-07-31 2007-10-03 Nucleonics Inc Double stranded rna structures and constructs, and methods for generating and using the same
US6921371B2 (en) 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
EP1629105B1 (en) * 2003-04-29 2010-09-01 AVI BioPharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US7025726B2 (en) * 2004-01-22 2006-04-11 The Regents Of The University Of Nebraska Detection of endothelial dysfunction by ultrasonic imaging
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
DE102004057196A1 (en) * 2004-11-26 2006-06-01 Rösner Research GmbH & Co.KG Method for producing albumin conjugates with non-steroidal anti-inflammatory drugs (NSAIDs)
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
WO2006129080A1 (en) * 2005-05-31 2006-12-07 The Institute Of Cancer Research: Royal Cancer Hospital Materials and methods for transducing cells with a viral vector
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8057408B2 (en) 2005-09-22 2011-11-15 The Regents Of The University Of Michigan Pulsed cavitational ultrasound therapy
US10219815B2 (en) 2005-09-22 2019-03-05 The Regents Of The University Of Michigan Histotripsy for thrombolysis
EP1968441A2 (en) * 2005-12-02 2008-09-17 Barnes-Jewish Hospital Methods to ameliorate and image angioplasty-induced vascular injury
US8715221B2 (en) 2006-03-08 2014-05-06 Fresenius Medical Care Holdings, Inc. Wearable kidney
US8012118B2 (en) 2006-03-08 2011-09-06 Fresenius Medical Care Holdings, Inc. Artificial kidney dialysis system
KR101419682B1 (en) 2006-08-24 2014-07-17 프레제니우스 메디칼 케어 홀딩스 인코퍼레이티드 Device for removing fluid from blood in a patient
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
US9044568B2 (en) 2007-06-22 2015-06-02 Ekos Corporation Method and apparatus for treatment of intracranial hemorrhages
CA2691673A1 (en) * 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2009043031A2 (en) 2007-09-27 2009-04-02 Children's Medical Center Corporation Microbubbles and methods for oxygen delivery
WO2009117688A2 (en) * 2008-03-21 2009-09-24 The Board Of Trustees Of The University Of Arkansas Methods for producing microbubbles
JP5551709B2 (en) 2008-11-03 2014-07-16 フレゼニウス メディカル ケア ホールディングス インコーポレイテッド Portable peritoneal dialysis system
CA2746508A1 (en) * 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011022411A2 (en) 2009-08-17 2011-02-24 Histosonics, Inc. Disposable acoustic coupling medium container
US9943708B2 (en) 2009-08-26 2018-04-17 Histosonics, Inc. Automated control of micromanipulator arm for histotripsy prostate therapy while imaging via ultrasound transducers in real time
AU2010289775B2 (en) 2009-08-26 2016-02-04 Histosonics, Inc. Devices and methods for using controlled bubble cloud cavitation in fractionating urinary stones
US10058837B2 (en) 2009-08-28 2018-08-28 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
US8539813B2 (en) 2009-09-22 2013-09-24 The Regents Of The University Of Michigan Gel phantoms for testing cavitational ultrasound (histotripsy) transducers
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
WO2012065060A2 (en) * 2010-11-12 2012-05-18 Children's Medical Center Corporation Gas-filled microbubbles and systems for gas delivery
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR20120140290A (en) * 2011-06-21 2012-12-31 주식회사 퍼시픽시스템 Method of manufacturing bubble for accelerating functional material and device or transferring functional material
US9144694B2 (en) 2011-08-10 2015-09-29 The Regents Of The University Of Michigan Lesion generation through bone using histotripsy therapy without aberration correction
US10357450B2 (en) 2012-04-06 2019-07-23 Children's Medical Center Corporation Process for forming microbubbles with high oxygen content and uses thereof
US9049783B2 (en) 2012-04-13 2015-06-02 Histosonics, Inc. Systems and methods for obtaining large creepage isolation on printed circuit boards
EP2844343B1 (en) 2012-04-30 2018-11-21 The Regents Of The University Of Michigan Ultrasound transducer manufacturing using rapid-prototyping method
WO2014055906A1 (en) 2012-10-05 2014-04-10 The Regents Of The University Of Michigan Bubble-induced color doppler feedback during histotripsy
WO2014117232A1 (en) * 2013-02-04 2014-08-07 Farret Neto Abdo Medicinal preparation in the form of a foam for the sustained release of medicinal drugs, and system for producing the medicinal preparation
US9101745B2 (en) 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
EP2968825A4 (en) 2013-03-15 2016-09-07 Childrens Medical Center Gas-filled stabilized particles and methods of use
AU2014232195A1 (en) * 2013-03-15 2015-10-15 Doheny Eye Institute Management of tractional membranes
US10124126B2 (en) * 2013-04-18 2018-11-13 The Regents Of The University Of Colorado, A Body Corporate System and methods for ventilation through a body cavity
WO2015003142A1 (en) 2013-07-03 2015-01-08 Histosonics, Inc. Histotripsy excitation sequences optimized for bubble cloud formation using shock scattering
WO2015003154A1 (en) 2013-07-03 2015-01-08 Histosonics, Inc. Articulating arm limiter for cavitational ultrasound therapy system
WO2015027164A1 (en) 2013-08-22 2015-02-26 The Regents Of The University Of Michigan Histotripsy using very short ultrasound pulses
US11305013B2 (en) * 2014-08-26 2022-04-19 Drexel University Surfactant microbubbles and process for preparing and methods of using the same
US10052394B2 (en) 2014-11-21 2018-08-21 General Electric Company Microbubble tether for diagnostic and therapeutic applications
RU2704823C2 (en) * 2015-05-28 2019-10-31 Пасифик Систем Ко., Лтд. Cavitation nucleus for drug delivery and method for drug delivery using same
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
WO2016201136A1 (en) 2015-06-10 2016-12-15 Ekos Corporation Ultrasound catheter
WO2016210133A1 (en) 2015-06-24 2016-12-29 The Regents Of The Universtiy Of Michigan Histotripsy therapy systems and methods for the treatment of brain tissue
SG10202012839TA (en) 2016-12-19 2021-01-28 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
US11147890B2 (en) 2017-02-28 2021-10-19 Children's Medical Center Corporation Stimuli-responsive particles encapsulating a gas and methods of use
CN113286552A (en) 2018-11-28 2021-08-20 希斯托索尼克斯公司 Histotripsy system and method
CA3169465A1 (en) 2020-01-28 2021-08-05 The Regents Of The University Of Michigan Systems and methods for histotripsy immunosensitization
WO2021155171A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Delivery of compositions comprising circular polyribonucleotides
TW202142689A (en) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 Compositions for translation and methods of use thereof
WO2021155177A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Compositions comprising linear polyribonucleotides for protein modulation and uses thereof
TW202206097A (en) 2020-05-20 2022-02-16 美商旗艦先鋒創新有限責任公司 Coronavirus antigen compositions and their uses
JP2023526423A (en) 2020-05-20 2023-06-21 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー Immunogenic compositions and uses thereof
WO2022051629A1 (en) 2020-09-03 2022-03-10 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
CA3232635A1 (en) 2021-09-17 2023-03-23 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
TW202322826A (en) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 Compositions and methods for purifying polyribonucleotides
WO2023097003A2 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
WO2023096990A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
WO2023122745A1 (en) 2021-12-22 2023-06-29 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
TW202342064A (en) 2021-12-23 2023-11-01 美商旗艦先鋒創新有限責任公司 Circular polyribonucleotides encoding antifusogenic polypeptides

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US5040537A (en) * 1987-11-24 1991-08-20 Hitachi, Ltd. Method and apparatus for the measurement and medical treatment using an ultrasonic wave
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US5410516A (en) * 1988-09-01 1995-04-25 Schering Aktiengesellschaft Ultrasonic processes and circuits for performing them
US4957656A (en) * 1988-09-14 1990-09-18 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
IN172208B (en) * 1990-04-02 1993-05-01 Sint Sa
US5445813A (en) * 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5315997A (en) * 1990-06-19 1994-05-31 Molecular Biosystems, Inc. Method of magnetic resonance imaging using diamagnetic contrast
US5310540A (en) * 1990-10-05 1994-05-10 Sintetica Sa Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography
US5107842A (en) * 1991-02-22 1992-04-28 Molecular Biosystems, Inc. Method of ultrasound imaging of the gastrointestinal tract
DE69215722T3 (en) * 1991-03-22 2001-03-08 Katsuro Tachibana Amplifiers for ultrasound therapy of diseases and liquid pharmaceutical compositions containing them
DE69230885T3 (en) * 1991-09-17 2008-01-24 Ge Healthcare As GASOUS ULTRASONIC CONTRASTING AGENTS
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
US5255683A (en) * 1991-12-30 1993-10-26 Sound Science Limited Partnership Methods of and systems for examining tissue perfusion using ultrasonic contrast agents
IL104084A (en) * 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5302372A (en) * 1992-07-27 1994-04-12 National Science Council Method to opacify left ventricle in echocardiography
DE4232755A1 (en) * 1992-09-26 1994-03-31 Schering Ag Microparticle preparations made from biodegradable copolymers
CN1068230C (en) * 1993-01-25 2001-07-11 索纳斯药品有限公司 Phase shift colloids as ultrasound contrast agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
BR9405798A (en) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Methods for in vivo release of biological material and useful compositions thereof
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5401493A (en) * 1993-03-26 1995-03-28 Molecular Biosystems, Inc. Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same
US5701899A (en) * 1993-05-12 1997-12-30 The Board Of Regents Of The University Of Nebraska Perfluorobutane ultrasound contrast agent and methods for its manufacture and use
US5567415A (en) * 1993-05-12 1996-10-22 The Board Of Regents Of The University Of Nebraska Ultrasound contrast agents and methods for their manufacture and use
US5695740A (en) * 1993-05-12 1997-12-09 The Board Of Regents Of The University Of Nebraska Perfluorocarbon ultrasound contrast agent comprising microbubbles containing a filmogenic protein and a saccharide
KR100218642B1 (en) * 1993-07-02 1999-09-01 스티븐 로손 Method of making microspheres encapsulated from the temperature-denaturated protein
US5385147A (en) * 1993-09-22 1995-01-31 Molecular Biosystems, Inc. Method of ultrasonic imaging of the gastrointestinal tract and upper abdominal organs using an orally administered negative contrast medium
NO940711D0 (en) * 1994-03-01 1994-03-01 Nycomed Imaging As Preparation of gas-filled microcapsules and contrast agents for diagnostic imaging
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US5560364A (en) * 1995-05-12 1996-10-01 The Board Of Regents Of The University Of Nebraska Suspended ultra-sound induced microbubble cavitation imaging
WO1997033474A1 (en) * 1996-03-12 1997-09-18 Board Of Regents Of The University Of Nebraska Targeted site specific drug delivery compositions and method of use
US5849727A (en) * 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents

Also Published As

Publication number Publication date
EP0938341A2 (en) 1999-09-01
CA2258882C (en) 2009-03-17
US7115583B2 (en) 2006-10-03
WO1998000172A2 (en) 1998-01-08
ATE260677T1 (en) 2004-03-15
US6537814B1 (en) 2003-03-25
US5849727A (en) 1998-12-15
US7198949B2 (en) 2007-04-03
US20040013662A1 (en) 2004-01-22
JP2009029810A (en) 2009-02-12
WO1998000172A3 (en) 1998-05-14
DE69727958T2 (en) 2005-04-07
JP4201348B2 (en) 2008-12-24
DE69727958D1 (en) 2004-04-08
US20040057946A1 (en) 2004-03-25
US6117858A (en) 2000-09-12
JP2000515499A (en) 2000-11-21
EP0938341B1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
CA2258882A1 (en) Compositions and methods for altering the biodistribution of biological agents
AU2207197A (en) Targeted site specific drug delivery compositions and method of use
CA2182228A1 (en) Codrugs as a method of controlled drug delivery
CA2318128A1 (en) Oral liquid compositions
CA2406650A1 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
CA2242035A1 (en) Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
IL139285A0 (en) Peg-lhrh analog conjugates, their preparation and use
YU73600A (en) Novel nucleosides having bicyclic sugar moiety
UA52594C2 (en) Cycloalcanopyridine derivatives, mixture of isomers thereof or individual isomers, their salts and n-oxides, methods and intermediate compounds for preparation thereof, a also a pharmaceutical composition
CA2257133A1 (en) Human dnase i hyperactive variants
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
HUP0204085A3 (en) New oxabispidine compounds useful in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
CA2449856A1 (en) Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
HUP0302538A3 (en) 3,7-diazabicyclo[3.3.0]oczanes and their use in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
CA2279184A1 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
CA2319542A1 (en) The treatment of sexual dysfunction in certain patient groups
FR2757514B1 (en) NOVEL CAMPTOTHECIN ANALOGS, PREPARATION METHODS, USE THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1999002120A3 (en) Compositions and methods for reversibly increasing permeability of biomembranes
HUP0102522A3 (en) 3',3'-n-bis-substituted macrolide lhrh antagonists and their use, process for their preparation and pharmaceutical compositions comprising them
HUP0102987A3 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
FR2702481B1 (en) New soluble human Fc-gamma III receptors, their preparation process, the pharmaceutical compositions containing them, their application as medicaments and their diagnostic application.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170620